Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Statement on Nuplazid Drug

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

The Parkinson’s Foundation is closely monitoring the recent reports on Nuplazid. At this time, we are recommending that patients on this drug consult with their neurologists about the risks and benefits of the treatment. The FDA will continue to monitor the drug’s use and safety, but they have not identified a specific safety issue that isn’t already described in the drug’s label. 

Parkinson’s disease psychosis is typically seen in advanced stages of Parkinson’s disease involving elderly patients. Treating Parkinson’s disease psychosis is a multi-step process that begins with talking to your health care team. They will follow a series of steps to figure out how best to address symptoms. For more information on this topic, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636). 

Please report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088. You can also call ACADIA Pharmaceuticals Inc. at 1‑844‑4ACADIA (1‑844‑422‑2342).

For more information about Psychosis and Parkinson’s Disease:

Listen to our podcast

Read our recent blog article

Read more in our free book, "Psychosis: A Mind Guide to Parkinson's Disease"

Watch our Expert Briefings: Parkinson's Disease Psychosis: Hallucinations, Delusions and Paranoia

Tuesday, April 10, 2018
Erin Borger and Paul Blom Join NPF's Board of Directors
Tuesday, January 13, 2015

MIAMI,FL — The National Parkinson Foundation (NPF) announced the election of two new members to its Board of Directors: Erin R. Borger and Paul R. Blom. 

FDA Approves Revolutionary Parkinson's Treatment and NPF Is Helping Deliver it to You
Monday, January 12, 2015

The National Parkinson Foundation (NPF) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved DUOPA™, developed by AbbVie Inc., as a treatment for people with advanced Parkinson's disease.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.